Title |
Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood–brain barrier model
|
---|---|
Published in |
Alzheimer's Research & Therapy, November 2013
|
DOI | 10.1186/alzrt225 |
Pubmed ID | |
Authors |
Sabrina Meister, Iavor Zlatev, Julia Stab, Dominic Docter, Sandra Baches, Roland H Stauber, Mordechai Deutsch, Reinhold Schmidt, Stefan Ropele, Manfred Windisch, Klaus Langer, Sylvia Wagner, Hagen von Briesen, Sascha Weggen, Claus U Pietrzik |
Abstract |
The amyloid-β42 (Aβ42) peptide plays a crucial role in the pathogenesis of Alzheimer's disease (AD), the most common neurodegenerative disorder affecting the elderly. Over the past years, several approaches and compounds developed for the treatment of AD have failed in clinical studies, likely in part due to their low penetration of the blood-brain barrier (BBB). Since nanotechnology-based strategies offer new possibilities for the delivery of drugs to the brain, this technique is studied intensively for the treatment of AD and other neurological disorders. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 1% |
Spain | 1 | 1% |
Poland | 1 | 1% |
Germany | 1 | 1% |
Unknown | 89 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 17 | 18% |
Student > Master | 17 | 18% |
Researcher | 13 | 14% |
Student > Bachelor | 10 | 11% |
Student > Doctoral Student | 8 | 9% |
Other | 15 | 16% |
Unknown | 13 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 22 | 24% |
Pharmacology, Toxicology and Pharmaceutical Science | 11 | 12% |
Medicine and Dentistry | 9 | 10% |
Engineering | 7 | 8% |
Biochemistry, Genetics and Molecular Biology | 6 | 6% |
Other | 18 | 19% |
Unknown | 20 | 22% |